Overview

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Status:
Active, not recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a type of cancer affecting the lining of the lung). Patients will receive an infusion (given by vein) of autologous tumor infiltrating lymphocytes (TILs). TILs are a type of white blood cells that recognizes tumor cells and enter them which causes the tumor cells to break down. Prior to the cell infusion, patients will receive a two drugs cyclophosphamide and fludarabine to prepare the body to receive the TILs. After cell infusion, patients will receive low-dose interleukin-2 therapy. This study will see how safe and useful this regimen is in treating malignant pleural mesothelioma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate
Interleukin-2
Vidarabine